Zydus Cadila Receives FDA Approval for Marketing Pioglitazone in US

by Kathy Jones on  February 15, 2013 at 9:23 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

Indian pharmaceutical firm Zydus Cadila revealed that it has received the final approval from the US Food and Drug Administration to market its anti-diabetic drug, Pioglitazone HCI, in the American market.
 Zydus Cadila Receives FDA Approval for Marketing Pioglitazone in US
Zydus Cadila Receives FDA Approval for Marketing Pioglitazone in US

Zydus announced that it has received approval to market Pioglitazone HCI tablets in 15 mg, 30 mg and 45 mg strengths. The company added that sales for Pioglitazone HCI tablets was estimated at $2 billion in 2012, according to data from IMS.

The company has so far filed over 170 Abbreviated New Drug Applications (ANDA) since 2003-04 and has so far received 75 approvals, including for the sale of oral tablets of Ultracet.


Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive